申请人:Pfizer Inc.
公开号:US04740513A1
公开(公告)日:1988-04-26
A series of novel heterocyclic-substituted 2-(1H)-quinolone compounds have been prepared wherein the heterocyclic ring moiety is a substituted pyrrolyl, imidazolyl, pyrazolyl, triazolyl or tetrazolyl group attached by a nitrogen atom of said group to the 5-, 6-, 7- or 8-positions of the quinolone ring. These particular compounds are useful in therapy as highly potent cardiac stimulants and therefore, are of value in the treatment of various cardiac conditions. Typical member compounds include those 6-(heterocyclic-substituted)-8-methyl-2-(1H)-quinolones wherein the heterocyclic ring moiety is a ring-substituted imidazol-1-yl group and preferably, an imidazol-1-yl group substituted with one or two methyl groups and a monoacetyl group. 6-(4-Acetyl-2-methylimidazol-1-yl)-8-methyl--2-(1H)-quinolone represents a typical and preferred member compound. Methods for preparing all these compounds from known starting materials are provided.
一系列新型的杂环取代的2-(1H)-喹啉化合物已经制备出来,其中杂环环基是通过其氮原子连接到喹啉环的5、6、7或8位置的取代吡咯基、咪唑基、吡唑基、三唑基或四唑基团。这些特定的化合物在治疗方面非常有用,是高效的心脏兴奋剂,因此对于治疗各种心脏疾病具有价值。典型的成员化合物包括那些6-(杂环取代)-8-甲基-2-(1H)-喹啉,其中杂环环基是环取代的咪唑-1-基团,最好是一个取代有一个或两个甲基基团和一个单乙酰基团的咪唑-1-基团。6-(4-乙酰基-2-甲基咪唑-1-基)-8-甲基-2-(1H)-喹啉代表了一个典型且优选的成员化合物。提供了从已知起始材料制备所有这些化合物的方法。